German Research Foundation (DFG):
Impact of soluble Flt-1 on endothelial cell activation and its implications in leukocyte adhesion and microvascular dysfunction in ischemia-reperfusion injury (SE 2824/3-1, 2019-2022)
Soluble Flt-1 in chronic kidney disease: sites of production, regulation and direct effects on heart vascularization in the rat 5/6 nephrectomy model (BR 2262/3-1, 2011-2013)
Else-Kröner-Fresenius Foundation (Bad Homburg, Germany):
Cellular therapy with bone marrow-derived cells in chronic kidney disease-associated heart injury (2013/A41, 2013-2016)
Cardiovascular disease in an animal model of kidney disease: the role of soluble vascular endothelial growth factor receptor 1 (sFlt1) and calcineurin inhibitors (P38/09 // A55/09, 2009-2011)
Dr. Werner Jackstädt Foundation (Wuppertal, Germany):
The association of soluble fms-like tyrosine kinase-1 (sFlt1) with adverse clinical outcomes following in-hospital acute kidney injury (AK) (2022-2024)
Innovative Medical Research (IMF; Münster, Germany):
Phosphate-induced metabolic reprogramming of macrophages as a driver of inflammation in chronic kidney disease (BO 112604, 2026-2029)
The role of soluble fms-like tyrosine kinase-1 (sFlt-1) on monocyte/macrophage activation (SE 211808, 2018-2019)
Elevated sFlt-1 levels after renal ischemia-reperfusion injury: regulations and implications (DI 111406, 2014-2017)
Diabetes and Angiogenesis: different responses to endothelin-1 (ET-1) and vascular endothelial growth facotr (VEGF) and the role of hemeoxygenase-1 (HO-1) (DI 220801, 2009)
CareerS Support modules at the Faculty of Medicine Münster (Germany):
CareerS Starter: The role of hyperphosphatemia in endothelial inflammation (Göran R. Boeckel, 2023-2024)
CareerS Boost: The role of hyperphosphatemia in endothelial inflammation (Göran R. Boeckel, 2024-2025)
German Society of Nephrology (DGfN):
The role of sFlt-1 in renal and cardiovascular remodeling in chronic kidney disease (2012).